[1] |
Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
|
[2] |
Brenner H,Kloor M,Pox CP.Colorectal cancer[J].Lancet,2014,383(9927):1490-1502.
|
[3] |
Bokemeyer C,Van Cutsem E,Rougier P,et al.Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials[J].Eur J Cancer,2012,48(10):1466-1475.
|
[4] |
Bokemeyer C,Bondarenko I,Makhson A,et al.Fluorouracil,leucovorin,and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer[J].J Clin Oncol,2009,27(5):663-671.
|
[5] |
Maughan TS,Adams RA,Smith CG,et al.Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MR COIN trial[J].Lancet,2011,377(9783):2103-2114.
|
[6] |
Chen D,Li L,Zhang X,et al.FOLFOX plus anti-epidermal growth factor receptor(EGFR)monoclonal antibody(mAb)is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer:a meta-analysis[J].Medicine(Baltimore),2018,97(10):e0097.
|
[7] |
Folprecht G,Hamann S,Schutte K,et al.Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer[J].BMC Cancer,2014,14:521.
|
[8] |
Price TJ,Peeters M,Kim TW,et al.Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT):a randomised,multicentre,open-label,non-inferiority phase 3 study[J].Lancet Oncol,2014,15(6):569-579.
|
[9] |
Pinto C,Barone CA,Girolomoni G,et al.Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy[J].Oncologist,2011,16(2):228-238.
|
[10] |
杨欣,李洪波,陈诚,等.金银花药性与功效的文献考证[J].中国实验方剂学杂志,2010,16(18):220-222.
|
[11] |
邓霁玲.金银花的药理作用研究与实际临床应用分析[J].医药前沿,2017,7(2):284-285.
|
[12] |
王亚琼,陈卫,钟水生,等.金银花清热解毒作用的血清代谢组学研究[J].中药材,2016,39(5):1129-1133.
|
[13] |
张海霖,王国蓉,张仕碧,等.金银花液热湿敷防治放疗加西妥昔单抗致皮肤反应的效果观察[J].中华护理杂志,2010,45(4):307-310.
|
[14] |
龙小丽,黄艳,庞凡.金银花煎液外敷治疗西妥昔单抗致痤疮样皮疹[J].护理学杂志,2011,26(9):34.
|
[15] |
杨剑霞,孙丽凯.复方金银花煎液湿热敷联合夫西地酸乳膏外用治疗分子靶向药物所致皮疹的效果观察[J].护理学报,2015,22(2):61-62.
|
[16] |
容怡英,何湘子,丘小芬,等.金银花联合玫瑰果油治疗爱必妥致皮肤毒性反应的效果观察[J].护理学报,2010,26(S1):155.
|
[17] |
戎煜明,丘惠娟,林晓平,等.中药内服加金银花外用治疗西妥昔单抗引起的痤疮样皮疹[J].中药材,2017,40(10):2472-2474.
|
[18] |
武惠丽,李毅,宁晓云,等.复方金银花煎液湿热敷与夫西地酸乳膏联合治疗靶向药物所致皮疹的临床疗效[J].现代生物医学进展,2017,17(27):5258-5261.
|
[23] |
庞瑞.金银花有效成分的药理学研究进展[J].陕西中医学院学报,2011,34(3):77-79.
|
[19] |
World Medical Association.World Medical Association Declaration of Helsinki:ethical principles for medical research involving human subjects[J].JAMA,2013,310(20):2191-2194.
|
[20] |
Nardone B,Nicholson K,Newman M,et al.Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1)and HER1/2 inhibitors in cancer patients[J].Clin Cancer Res,2010,16(17):4452-4460.
|
[21] |
CunninghamD,HumbletY,SienaS,etal.Cetuximabmonotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[J].N Engl J Med,2004,351(4):337-345.
|
[22] |
Lacouture ME,Lai SE.The PRIDE (Papulopustules and/or paronychia,regulatory abnormalities of hair growth,itching,and dryness due to epidermal growth factor receptor inhibitors)syndrome[J].Br J Dermatol,2006,155(4):852-854.
|
[24] |
张百霞,周凤琴,郭庆梅.金银花中黄酮类化合物的研究进展[J].中国实验方剂学杂志,2012,18(23):2013-2014.
|
[25] |
陈继明,洪超群.金银花药理作用分析[J].亚太传统医药,2013,11(5):43-44.
|
[26] |
Lee GH,alietzis G,Askari A,et al.Is right-sided colon cancer different to left-sided colorectal cancer?-a systematic review[J].Eur J Surg Oncol,2015,41(3):300-308.
|